Dannielle Appelhans to succeed John Puisis as Cour CEO

A change at the top is on the way at Cour Pharmaceuticals, a privately-held US biotech developing disease-modifying therapies designed to induce antigen-specific tolerance for immune-mediated diseases.

As part of a leadership succession plan, John Puisis will transition his responsibilities as president and chief executive of Cour to the company’s chief operating officer (COO), Dannielle Appelhans (pictured, above), effective September 1.

Mr Puisis, who founded and led Cour through multiple INDs, clinical studies and strategic partnerships, will continue to serve in his role on the company’s board of directors and will be an advisor to the company through the end of 2024.